4:28 PM
 | 
Nov 02, 2018
 |  BioCentury  |  Finance

Bye-bye, build-to-buy

Why Versant is moving away from the build-to-buy model

As another Inception Sciences Inc. company secures an exit, Versant Ventures plans to move away from its build-to-buy model to focus on creating stand-alone companies with broader portfolios and investor syndicates.

On Oct. 31, Ophthotech Corp. (NASDAQ:OPHT) acquired Inception 4 Inc., gaining small molecule inhibitors of HtrA serine peptidase 1 (HTRA1) to treat age-related retinal diseases, including dry age-related macular degeneration (AMD). Ophthotech plans to submit an IND for its lead HTRA1 inhibitor in late 2020.

Versant gained a 12.5% stake in Ophthotech and is eligible for contingency payments upon completion of clinical and commercial milestones. Details weren’t disclosed.

Inception 4 was initially launched under a build-to-buy deal with Bayer AG (Xetra:BAYN); however,...

Read the full 554 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >